Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study.
Bersanelli M, Verzoni E, Cortellini A, Giusti R, Calvetti L, Ermacora P, Di Napoli M, Catino A, Guadalupi V, Guaitoli G, Scotti V, Mazzoni F, Veccia A, Guglielmini PF, Perrone F, Maruzzo M, Rossi E, Casadei C, Montesarchio V, Grossi F, Rizzo M, Travagliato Liboria MG, Mencoboni M, Zustovich F, Fratino L, Accettura C, Cinieri S, Camerini A, Sorarù M, Zucali PA, Ricciardi S, Russo A, Negrini G, Banzi MC, Lacidogna G, Fornarini G, Laera L, Mucciarini C, Santoni M, Mosillo C, Bonetti A, Longo L, Sartori D, Baldini E, Guida M, Iannopollo M, Bordonaro R, Morelli MF, Tagliaferri P, Spada M, Ceribelli A, Silva RR, Nolè F, Beretta G, Giovanis P, Santini D, Luzi Fedeli S, Nanni O, Maiello E, Labianca R, Pinto C, Clemente A, Tognetto M, De Giorgi U, Pignata S, Di Maio M, Buti S, Giannarelli D; FICOG group (Federation of Italian Cooperative Oncology Groups). Bersanelli M, et al. Among authors: tognetto m. EClinicalMedicine. 2023 Jun 29;61:102044. doi: 10.1016/j.eclinm.2023.102044. eCollection 2023 Jul. EClinicalMedicine. 2023. PMID: 37434748 Free PMC article.
Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG.
Bersanelli M, Giannarelli D, De Giorgi U, Pignata S, Di Maio M, Verzoni E, Clemente A, Guadalupi V, Signorelli D, Tiseo M, Giusti R, Filetti M, Di Napoli M, Calvetti L, Cappetta A, Ermacora P, Zara D, Barbieri F, Baldessari C, Scotti V, Mazzoni F, Veccia A, Guglielmini PF, Maruzzo M, Rossi E, Grossi F, Casadei C, Cortellini A, Verderame F, Montesarchio V, Rizzo M, Mencoboni M, Zustovich F, Fratino L, Cinieri S, Negrini G, Banzi M, Sorarù M, Zucali PA, Lacidogna G, Russo A, Battelli N, Fornarini G, Mucciarini C, Bracarda S, Bonetti A, Pezzuolo D, Longo L, Sartori D, Iannopollo M, Cavanna L, Meriggi F, Tassinari D, Corbo C, Gernone A, Prati V, Carnio S, Giordano P, Dicorato AM, Verusio C, Atzori F, Carrozza F, Gori S, Castro A, Pilotto S, Vaccaro V, Garzoli E, Di Costanzo F, Maiello E, Labianca R, Pinto C, Tognetto M, Buti S. Bersanelli M, et al. Among authors: tognetto m. Ther Adv Med Oncol. 2020 Nov 2;12:1758835920968463. doi: 10.1177/1758835920968463. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 33224275 Free PMC article.
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2).
Bersanelli M, Giannarelli D, De Giorgi U, Pignata S, Di Maio M, Clemente A, Verzoni E, Giusti R, Di Napoli M, Aprile G, Ermacora P, Catino A, Scotti V, Mazzoni F, Guglielmini PF, Veccia A, Maruzzo M, Rossi E, Grossi F, Casadei C, Ficorella C, Montesarchio V, Verderame F, Rizzo M, Guaitoli G, Fratino L, Accettura C, Mencoboni M, Zustovich F, Baldessari C, Cinieri S, Camerini A, Laera L, Sorarù M, Zucali PA, Guadalupi V, Leonardi F, Tiseo M, Tognetto M, Di Costanzo F, Pinto C, Negrini G, Russo A, Migliorino MR, Filetti M, Buti S; FICOG group (Federation of Italian Cooperative Oncology Groups). Bersanelli M, et al. Among authors: tognetto m. J Immunother Cancer. 2021 May;9(5):e002619. doi: 10.1136/jitc-2021-002619. J Immunother Cancer. 2021. PMID: 34016723 Free PMC article.
Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy.
Bersanelli M, Zielli T, Perrone F, Casartelli C, Pratticò F, Rapacchi E, Camisa R, Tognetto M, Clemente A, Giannarelli D, Rebuzzi SE, Leonetti A, Bordi P, Tiseo M, Buti S. Bersanelli M, et al. Among authors: tognetto m. Immunotherapy. 2020 Oct;12(15):1139-1148. doi: 10.2217/imt-2020-0211. Epub 2020 Sep 15. Immunotherapy. 2020. PMID: 32933369 Free PMC article.
A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale.
Andrini E, Lamberti G, Mazzoni F, Riccardi F, Bonetti A, Follador A, Artioli F, Genova C, Barbieri F, Frassoldati A, Brighenti M, Colantonio I, Pasello G, Ficorella C, Cinieri S, Tiseo M, Gelsomino F, Tognetto M, Rihawi K, Ardizzoni A. Andrini E, et al. Among authors: tognetto m. Future Oncol. 2022 Mar;18(7):771-779. doi: 10.2217/fon-2021-1027. Epub 2022 Jan 24. Future Oncol. 2022. PMID: 35068173
The pharmacological costs of complete liver resections in unselected advanced colorectal cancer patients: a review of published Phase II and III trials.
Giuliani J, Mercanti A, Muraro S, Trolese AR, Durante E, Greco F, Piacentini P, Tognetto M, Bonetti A. Giuliani J, et al. Among authors: tognetto m. Expert Rev Pharmacoecon Outcomes Res. 2015 Feb;15(1):101-10. doi: 10.1586/14737167.2015.982099. Epub 2014 Nov 15. Expert Rev Pharmacoecon Outcomes Res. 2015. PMID: 25399933 Review.
Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial).
Gelsomino F, Lamberti G, Tiseo M, Rocco D, Pasello G, Cecere FL, Chella A, Grilli G, Mandruzzato M, Tognetto M, Garassino MC, Macerelli M, Novello S, Roila F, Colantonio I, Grossi F, Fiorentino M, Ardizzoni A. Gelsomino F, et al. Among authors: tognetto m. Ther Adv Med Oncol. 2020 Jul 20;12:1758835920915983. doi: 10.1177/1758835920915983. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 32733604 Free PMC article.
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).
Pellegrino B, Cavanna L, Boggiani D, Zamagni C, Frassoldati A, Schirone A, Caldara A, Rocca A, Gori S, Piacentini F, Berardi R, Brandes AA, Foglietta J, Villa F, Todeschini R, Tognetto M, Naldi N, Bortesi B, Montemurro F, Ardizzoni A, Boni L, Musolino A. Pellegrino B, et al. Among authors: tognetto m. ESMO Open. 2021 Feb;6(1):100019. doi: 10.1016/j.esmoop.2020.100019. Epub 2020 Dec 31. ESMO Open. 2021. PMID: 33399082 Free PMC article. Clinical Trial.
29 results